{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:22:13Z","timestamp":1781976133215,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81500916"],"award-info":[{"award-number":["81500916"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870988"],"award-info":[{"award-number":["81870988"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071410"],"award-info":[{"award-number":["82071410"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.clim.2022.109058","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T16:11:11Z","timestamp":1654791071000},"page":"109058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: A prospective cohort study"],"prefix":"10.1016","volume":"241","author":[{"given":"Yuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Huan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ying","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianquan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2022.109058_bb0005","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clim.2022.109058_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102800","article-title":"The role of innate immunity in myasthenia gravis","volume":"20","author":"Zhao","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.clim.2022.109058_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.593431","article-title":"Immunoregulatory cells in myasthenia gravis","volume":"11","author":"Wu","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clim.2022.109058_bb0020","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clim.2022.109058_bb0025","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.clim.2022.109058_bb0030","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2022.109058_bb0035","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2022.109058_bb0040","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/00003246-199707000-00027","article-title":"Therapy of myasthenic crisis","volume":"25","author":"Berrouschot","year":"1997","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.clim.2022.109058_bb0045","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","article-title":"Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases","volume":"94","author":"Neumann","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2022.109058_bb0050","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/ene.12115","article-title":"Myasthenia gravis--treatment of acute severe exacerbations in the intensive care unit results in a favourable long-term prognosis","volume":"21","author":"Spillane","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clim.2022.109058_bb0055","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2022.109058_bb0060","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acn3.51312","article-title":"In-depth peripheral CD4(+) T profile correlates with myasthenic crisis","volume":"8","author":"Huan","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.clim.2022.109058_bb0065","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clim.2022.109058_bb0070","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2022.109058_bb0075","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2022.109058_bb0080","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1007\/s00415-021-10603-9","article-title":"MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation","volume":"268","author":"Konig","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2022.109058_bb0085","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1002\/acn3.50901","article-title":"Clinical outcome measures following plasma exchange for MG exacerbation","volume":"6","author":"Raja","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.clim.2022.109058_bb0090","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clim.2022.109058_bb0095","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group","volume":"326","author":"van der Meche","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2022.109058_bb0100","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1468-1331.2009.02729.x","article-title":"Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis","volume":"16","author":"Yeh","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clim.2022.109058_bb0105","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/j.1468-1331.2011.03424.x","article-title":"Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis","volume":"18","author":"Chien","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clim.2022.109058_bb0110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000014434","article-title":"Soluble adhesion molecules and cytokines in patients with myasthenia gravis treated by plasma exchange","volume":"18","author":"Tesar","year":"2000","journal-title":"Blood Purif."},{"key":"10.1016\/j.clim.2022.109058_bb0115","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1212\/WNL.0000000000004676","article-title":"Myasthenia Gravis Impairment Index: responsiveness, meaningful change, and relative efficiency","volume":"89","author":"Barnett","year":"2017","journal-title":"NEUROLOGY"},{"key":"10.1016\/j.clim.2022.109058_bb0120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","article-title":"Efficacy of intravenous immunoglobulin in neurological diseases","volume":"13","author":"Lunemann","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.clim.2022.109058_bb0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology--mode of action and clinical efficacy","volume":"11","author":"Lunemann","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.clim.2022.109058_bb0130","doi-asserted-by":"crossref","first-page":"3645157","DOI":"10.1155\/2020\/3645157","article-title":"Defects of CTLA-4 are associated with regulatory T cells in myasthenia gravis implicated by intravenous immunoglobulin therapy","volume":"2020","author":"Xu","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.clim.2022.109058_bb0135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jca.21554","article-title":"Hospital-acquired anemia due to diagnostic and therapy-related blood loss in inpatients with myasthenia gravis receiving therapeutic plasma exchange","volume":"33","author":"Mann","year":"2018","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.clim.2022.109058_bb0140","first-page":"273","article-title":"New onset Iron deficiency anemia in chronic therapeutic plasma exchange patients","volume":"48","author":"Compton","year":"2018","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.clim.2022.109058_bb0145","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1111\/j.1537-2995.2008.01721.x","article-title":"Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis","volume":"48","author":"Daw","year":"2008","journal-title":"TRANSFUSION"},{"issue":"Suppl. 2","key":"10.1016\/j.clim.2022.109058_bb0150","first-page":"S59","article-title":"Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports","volume":"55","author":"Padmore","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.clim.2022.109058_bb0155","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/jca.10000","article-title":"Hypocalcemic toxicity and atypical reactions in therapeutic plasma exchange","volume":"16","author":"Weinstein","year":"2001","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.clim.2022.109058_bb0160","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/jca.20142","article-title":"Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange","volume":"22","author":"Kankirawatana","year":"2007","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.clim.2022.109058_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103147","article-title":"Effectiveness of supplemental oral calcium drink in preventing citrate-related adverse effects in peripheral blood progenitor cell collection","volume":"60","author":"Fujii","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.clim.2022.109058_bb0170","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-022-11023-z","article-title":"Seronegative myasthenic crisis: a multicenter analysis","author":"Mergenthaler","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2022.109058_bb0175","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.bbmt.2011.10.030","article-title":"Clinical trials in BMT: ensuring that rare diseases and rarer therapies are well done","volume":"18","author":"Shurin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clim.2022.109058_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g6802","article-title":"Innovative research methods for studying treatments for rare diseases: methodological review","volume":"349","author":"Gagne","year":"2014","journal-title":"BMJ"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622001395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622001395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:07:47Z","timestamp":1761494867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661622001395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":36,"alternative-id":["S1521661622001395"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2022.109058","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2022.109058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109058"}}